#73 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
🧠 While anecdotal reports and preclinical studies suggest cannabidiol (CBD) may modulate the endocannabinoid system to reduce inflammation and provide neuroprotection, the clinical evidence for CBD’s efficacy in pain management remains limited and inconsistent across human trials. Marketing claims about cannabis products often outpace the quality of supporting research, and clinicians should be cautious of oversimplified mechanistic explanations, particularly given confounders such as publication bias, variable product quality and labeling accuracy, and the placebo effect’s substantial role in pain perception. The endocannabinoid system’s role in pain and inflammation is biologically plausible, but translating this to meaningful clinical benefit requires rigorous randomized controlled trials with adequate dosing protocols and patient populations. Until robust evidence emerges, clinicians should counsel patients that cannabis or CBD for pain remains largely experimental, discuss potential drug interactions and regulatory gaps, and
💬 Join the Conversation
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
